Metabolomics analysis of antiquitin deficiency in cultured human cells and plasma: Relevance to pyridoxine‐dependent epilepsy. Issue 1 (27th October 2022)
- Record Type:
- Journal Article
- Title:
- Metabolomics analysis of antiquitin deficiency in cultured human cells and plasma: Relevance to pyridoxine‐dependent epilepsy. Issue 1 (27th October 2022)
- Main Title:
- Metabolomics analysis of antiquitin deficiency in cultured human cells and plasma: Relevance to pyridoxine‐dependent epilepsy
- Authors:
- Crowther, Lisa M.
Poms, Martin
Zandl‐Lang, Martina
Abela, Lucia
Hartmann, Hans
Seiler, Michelle
Mathis, Déborah
Plecko, Barbara - Abstract:
- Abstract: Deficiency of antiquitin (α‐aminoadipic semialdehyde dehydrogenase), an enzyme involved in lysine degradation and encoded by ALDH7A1, is the major cause of vitamin B6 ‐dependent epilepsy (PDE‐ALDH7A1). Despite seizure control with high dose pyridoxine (PN), developmental delay still occurs in approximately 70% of patients. We aimed to investigate metabolic perturbations due to possible previously unidentified roles of antiquitin, which may contribute to developmental delay, as well as metabolic effects of high dose pyridoxine supplementation reflecting the high doses used for seizure control in patients with PDE‐ALDH7A1. Untargeted metabolomics by high resolution mass spectrometry (HRMS) was used to analyze plasma of patients with PDE‐ALDH7A1 and two independently generated lines of cultured ReNcell CX human neuronal progenitor cells (NPCs) with CRISPR/Cas mediated antiquitin deficiency. Accumulation of lysine pathway metabolites in antiquitin‐deficient NPCs and western‐blot analysis confirmed knockdown of ALDH7A1 . Metabolomics analysis of antiquitin‐deficient NPCs in conditions of lysine restriction and PN supplementation identified changes in metabolites related to the transmethylation and transsulfuration pathways and osmolytes, indicating a possible unrecognized role of antiquitin outside the lysine degradation pathway. Analysis of plasma samples of PN treated patients with PDE‐ALDH7A1 and antiquitin‐deficient NPCs cultured in conditions comparable to theAbstract: Deficiency of antiquitin (α‐aminoadipic semialdehyde dehydrogenase), an enzyme involved in lysine degradation and encoded by ALDH7A1, is the major cause of vitamin B6 ‐dependent epilepsy (PDE‐ALDH7A1). Despite seizure control with high dose pyridoxine (PN), developmental delay still occurs in approximately 70% of patients. We aimed to investigate metabolic perturbations due to possible previously unidentified roles of antiquitin, which may contribute to developmental delay, as well as metabolic effects of high dose pyridoxine supplementation reflecting the high doses used for seizure control in patients with PDE‐ALDH7A1. Untargeted metabolomics by high resolution mass spectrometry (HRMS) was used to analyze plasma of patients with PDE‐ALDH7A1 and two independently generated lines of cultured ReNcell CX human neuronal progenitor cells (NPCs) with CRISPR/Cas mediated antiquitin deficiency. Accumulation of lysine pathway metabolites in antiquitin‐deficient NPCs and western‐blot analysis confirmed knockdown of ALDH7A1 . Metabolomics analysis of antiquitin‐deficient NPCs in conditions of lysine restriction and PN supplementation identified changes in metabolites related to the transmethylation and transsulfuration pathways and osmolytes, indicating a possible unrecognized role of antiquitin outside the lysine degradation pathway. Analysis of plasma samples of PN treated patients with PDE‐ALDH7A1 and antiquitin‐deficient NPCs cultured in conditions comparable to the patient plasma samples demonstrated perturbation of metabolites of the gamma‐glutamyl cycle, suggesting potential oxidative stress‐related effects in PN‐treated patients with PDE‐ALDH7A1. We postulate that a model of human NPCs with CRISPR/Cas mediated antiquitin deficiency is well suited to characterize previously unreported roles of antiquitin, relevant to this most prevalent form of pyridoxine‐dependent epilepsy. … (more)
- Is Part Of:
- Journal of inherited metabolic disease. Volume 46:Issue 1(2023)
- Journal:
- Journal of inherited metabolic disease
- Issue:
- Volume 46:Issue 1(2023)
- Issue Display:
- Volume 46, Issue 1 (2023)
- Year:
- 2023
- Volume:
- 46
- Issue:
- 1
- Issue Sort Value:
- 2023-0046-0001-0000
- Page Start:
- 129
- Page End:
- 142
- Publication Date:
- 2022-10-27
- Subjects:
- antiquitin deficiency -- lysine catabolism -- metabolomics -- NPCs -- PDE‐ALDH7A1 -- pyridoxine
Metabolism, Inborn errors of -- Periodicals
Metabolism -- Disorders -- Periodicals
616.39042 - Journal URLs:
- http://www.springer.com/gb/ ↗
- DOI:
- 10.1002/jimd.12569 ↗
- Languages:
- English
- ISSNs:
- 0141-8955
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5006.950000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25021.xml